1-4 of 4
Ken Kobayashi, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Jorge E. Cortes, MD, Samer K. Khaled, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Siddhartha Ganguly, MD, Nigel H. Russell, Alwin Kramer, MD, Herve Dombret, MD, Donna Hogge, Brian A. Jonas, MD PhD, Anskar Y.-H. Leung, MD PhD, Priyanka Mehta, Pau Montesinos, MD PhD, Markus P. Radsak, MD, Simona Sica, MD, Meena Arunachalam, Melissa Holmes, Ken Kobayashi, MD, Ruth Namuyinga, MD MPH, Nanxiang Ge, Antoine Yver, MD, Yufen Zhang, Mark J. Levis, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 563.
https://doi.org/10.1182/blood-2018-99-110439
Published: 2018
Journal Articles

Development of a Novel Next-Generation Sequencing (NGS)-Based Assay for Measurable Residual Disease (MRD) in FLT3 -ITD AML and Its Potential Clinical Application in Patients Treated with Chemotherapy Plus FLT3 Inhibitors

Mark J. Levis, MD, Wenge Shi, PhD, Ken CN Chang, PhD, Christian Laing, PhD, Flora Berisha, MS, Emily Adams, BS, MB(ASCP)CM, Christopher D Gocke, MD, Wei Ding, PhD, Kenji Nakamaru, Jelveh Lameh, PhD, Reinhold Pollner, Ken Kobayashi, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1459.
https://doi.org/10.1182/blood-2018-99-110438
Published: 2018
Journal Articles

Concordance between Bone Marrow and Peripheral Blood Samples for Assessment of FLT3 Internal Tandem Duplication (ITD) Mutations: Data from Patients Screened for Participation in Quantum-R, a Global, Randomized, Open-Label, Phase 3 Study Examining the Effect of Quizartinib Monotherapy Vs Salvage Chemotherapy on Overall Survival in Patients with FLT3 - ITD - Mutated AML Who Are Refractory to or Have Relapsed after First-Line Therapy

Samer Khaled, MD, Siddhartha Ganguly, MD, Alexander E. Perl, MD, Ken Kobayashi, MD, Flora Berisha, MS, Wei Ding, PhD, Jelveh Lameh, PhD, Giovanni Martinelli, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1424.
https://doi.org/10.1182/blood.V130.Suppl_1.1424.1424
Published: 2017
Journal Articles

Phase I and Pharmacokinetic (PK) Study of Everolimus (RAD001) in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL).

Michinori Ogura, MD, PhD, Toshiki Uchida, MD, PhD, Dai Maruyama, MD, PhD, Naokuni Uike, MD, PhD, IIseung Choi, MD, PhD, Kenichi Ishizawa, MD, PhD, Kuniaki Itoh, MD, PhD, Kiyoshi Ando, MD, PhD, Masafumi Taniwaki, MD, PhD, Naomi Shimada, Ken Kobayashi, MD, Kensei Tobinai, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1712.
https://doi.org/10.1182/blood.V114.22.1712.1712
Published: 2009